...Amy D. Shapiro A novel investigational product, recombinant factor VIla, manufactured by Novo Nordisk, is presently in clinical trial for evaluation of safety and efficacy when used in the home setting in patients with hemophilia A and B with inhibitors for control of hemostasis in mild to moderate...

... recombinant factor VIla (65-80 μg/kg) in 3 hemophilia A patients with a high titer of factor VIII inhibitors. TEG was more suitable than APTT, because r, r+k and ma values of TEG were normalized at least for 4 h after the infusion, whereas APTT was variably shortened and was not always maintained at a normal...

...R. Mølskov Bech Recombinant factor Vila (rFVIIa) improves haemostasis and eliminates the risk of transmission of blood-borne infection in haemophilia patients with inhibitors, acquired inhibitors to factor VIII or IX or FVII deficiency. rFVIIa has been available on a compassionate use basis since...

...K.M. Rice; G.F. Savidge Data is presented from two compassionate-use clinical trials using recombinant factor VIla (rFVIIa) to treat central nervous system haemorrhage in 18 haemophilia A and B patients with inhibitors, and in 3 patients with FVII deficiency. Prior to rFVIIa treatment 78...

...Jean McPherson; Lochie Teague; John Lloyd; David Jupe; John Rowell; Paul Ockelford; Henry Ekert; Alison Street; Amanda Faase; Ulla Hedner Recombinant factor Vila (rFVIIa; NovoSeven TM ) was available for compassionate use in Australia and New Zealand from 1991 to 1994. Over this period there were...

... inhibitors have complicated the clinical picture, and in whom a surgical procedure was indicated. As part of a compassionate use program devised by the producer of this genetically engineered factor VIla, 12 patients underwent life-saving or essential surgery where the recombinant factor VIla product...

.... Recombinant factor VIla Thrombocytopenia Bleeding time M «rm osI;isis S e ssio n IV: Clinical Experience w ith IM ovoSeven (rFVIIa) Haemostasis 1996;26(suppl 1): 159-164 Jörgen Kristemena Andreas Killandera Erik Hippec Carsten Hellebergc Jörgen Ellegdrdd Mette Holm6 Jack KuttP Ulf-Henrik Mellqvistb Jan...

... to in the content or advertisements. Von Willebrand’s disease Inhibitor Recombinant factor VIla Oral surgery Treatment Session IV: Clinical Experience with NovoSeven (rFVIIa) Haemostasis 1996;26(suppl 1): 150-154 N. Ciavarellaa M. Schiavonia E. Valenzanoa F. Manginib F. Inchingolob a Servizio di...